Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double-blind trial

Clin Ther. 2000 Jul;22(7):834-44. doi: 10.1016/S0149-2918(00)80056-9.

Abstract

Background: Dementia is a cerebral disorder resulting in a progressive deterioration of intellectual function that compromises the patient's ability to function. The diagnostic criteria for dementia are primarily clinical and are based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. The Hachinski score and computed tomography of the brain help distinguish between degenerative and vascular dementias.

Objective: This study examined the efficacy of naftidrofuryl in patients with vascular or mixed dementia.

Methods: This multicenter, randomized, double-blind study compared naftidrofuryl 600 mg/d with placebo for 1 year in patients with vascular or mixed dementia. A preliminary 2-month washout period allowed selection of patients who were compliant with treatment. The end point was change in the scores on the Alzheimer Disease Assessment Scale cognitive subscale and the Mini-Mental State Examination.

Results: Eighty-four patients were assessable on an intent-to-treat basis, and 74 were assessable for the per-protocol analysis (on-treatment). Statistically significant improvements in cognitive and global function were observed in patients receiving naftidrofuryl. Naftidrofuryl was well tolerated, and produced no clinically significant abnormalities in laboratory test results.

Conclusion: The results of this study suggest that naftidrofuryl is effective and well tolerated in treating the symptoms of vascular and mixed dementia.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Dementia / drug therapy*
  • Dementia, Vascular / drug therapy*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Nafronyl / adverse effects
  • Nafronyl / therapeutic use*
  • Placebos
  • Serotonin Antagonists / adverse effects
  • Serotonin Antagonists / therapeutic use*
  • Treatment Outcome

Substances

  • Placebos
  • Serotonin Antagonists
  • Nafronyl